Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.84 USD | +1.97% | +3.57% | -20.59% |
05-10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
05-10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.59% | 2.12B | |
+7.76% | 111B | |
+11.24% | 106B | |
-12.35% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.61% | 16.81B | |
+38.91% | 12.54B | |
-24.32% | 8.09B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Rocket Pharmaceuticals Sees 'Positive' Early Trial Data for RP-A501 in Danon Disease